| Prev Close | 185.61 |
| Day Low/High | 185.69 / 186.87 |
| 52 Wk Low/High | 114.27 / 186.91 |
| Avg Volume | 2.30M |
Allergan Plc (AGN)
186.64
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 328.28M |
| Market Cap | 60.82B |
| EPS | -15.30 |
| P/E Ratio | N/A |
| Div & Yield | 2.96 (1.60%) |
Latest News
The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
The Long Decline in AbbVie Is Over
In addition to the yield let's check out the charts of ABBV.
Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?
Right now, AbbVie is the best way to capitalize on the moment and on the future.
My Outlook for the Market's Major Sectors
* Only three of eleven S&P sectors are viewed as attractive * I am in a risk off state of mind. Back in 2015 I instituted a new regular feature called "Sectors," in which I periodically offered my short-term (6-12 months) price outlook for each of t...
These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Evolus Could See Breakout Soon
EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.
AbbVie: The Right Mixture for the Perfect Stock
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Powell's Verbal Fouls, an Equity Beatdown and Silence of the Lam: Market Recon
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Jim Cramer: Don't Play Earnings Season, Invest in It
Here are my five rules for handling earnings season.
Buyout Speculation Picks Up in Biotech
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
AbbVie Insiders Buying Shares
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
Now at the Plate, Your Pinch Hitter, Bret Jensen!
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
My 3 Predictions for the Second Half of 2019
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
I Believe AbbVie and Allergan Need Each Other
With no other bidder expected to emerge, this is a high risk arbitrage play.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
